These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 15703503

  • 1. Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
    Lindgren P, Buxton M, Kahan T, Poulter NR, Dahlöf B, Sever PS, Wedel H, Jönsson B, ASCOT investigators.
    Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):29-36. PubMed ID: 15703503
    [Abstract] [Full Text] [Related]

  • 2. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
    Sever PS, Poulter NR, Dahlof B, Wedel H, ASCOT Investigators.
    J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
    [Abstract] [Full Text] [Related]

  • 3. Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA).
    Sever PS, Poulter NR, Dahlöf B, Wedel H, Anglo-Scandinavian Cardiac Outcomes Trial Investigators.
    Am J Cardiol; 2005 Sep 05; 96(5A):39F-44F. PubMed ID: 16126022
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD, Rattinger GB, Kuznik A, Koren MJ.
    Clin Ther; 2008 Sep 05; 30 Pt 2():2204-16. PubMed ID: 19281915
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
    Wagner M, Goetghebeur M, Merikle E, Pandya A, Chu P, Taylor DC.
    Can J Clin Pharmacol; 2009 Sep 05; 16(2):e331-45. PubMed ID: 19531812
    [Abstract] [Full Text] [Related]

  • 6. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
    Liew D, Park HJ, Ko SK.
    Clin Ther; 2009 Oct 05; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
    [Abstract] [Full Text] [Related]

  • 7. A pharmacoeconomic evaluation of aggressive cholesterol lowering in Sweden.
    Olsson A, Casciano R, Stern L, Svangren P.
    Int J Cardiol; 2004 Jul 05; 96(1):51-7. PubMed ID: 15203261
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin.
    Lindgren P, Graff J, Olsson AG, Pedersen TJ, Jönsson B, IDEAL Trial Investigators.
    Eur Heart J; 2007 Jun 05; 28(12):1448-53. PubMed ID: 17371782
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: results from the Treating to New Targets (TNT) Trial.
    Mark DB, Knight JD, Cowper PA, Davidson-Ray L, Anstrom KJ.
    Am Heart J; 2008 Oct 05; 156(4):698-705. PubMed ID: 18926150
    [Abstract] [Full Text] [Related]

  • 11. Impact of statin therapy on central aortic pressures and hemodynamics: principal results of the Conduit Artery Function Evaluation-Lipid-Lowering Arm (CAFE-LLA) Study.
    Williams B, Lacy PS, Cruickshank JK, Collier D, Hughes AD, Stanton A, Thom S, Thurston H, CAFE and ASCOT Investigators.
    Circulation; 2009 Jan 06; 119(1):53-61. PubMed ID: 19103995
    [Abstract] [Full Text] [Related]

  • 12. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
    Hirsch M, O'Donnell JC, Jones P.
    Eur J Cardiovasc Prev Rehabil; 2005 Feb 06; 12(1):18-28. PubMed ID: 15703502
    [Abstract] [Full Text] [Related]

  • 13. The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1.
    Lindgren P, Buxton M, Kahan T, Poulter NR, Dahlöf B, Sever PS, Wedel H, Jönsson B, ASCOT investigators.
    Pharmacoeconomics; 2009 Feb 06; 27(3):221-30. PubMed ID: 19354342
    [Abstract] [Full Text] [Related]

  • 14. Lipid-lowering therapy and the patient with multiple risk factors: what have we learned from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)?
    Sever PS.
    Am J Med; 2005 Dec 06; 118 Suppl 12A():3-9. PubMed ID: 16356801
    [Abstract] [Full Text] [Related]

  • 15. Cost effectiveness of HMG-CoA reductase inhibition in Canada.
    Russell MW, Huse DM, Miller JD, Kraemer DF, Hartz SC.
    Can J Clin Pharmacol; 2001 Dec 06; 8(1):9-16. PubMed ID: 11283756
    [Abstract] [Full Text] [Related]

  • 16. A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels.
    Maclaine GD, Patel H.
    Int J Clin Pract; 2001 May 06; 55(4):243-9. PubMed ID: 11406909
    [Abstract] [Full Text] [Related]

  • 17. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
    Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, ASCOT Investigators.
    Drugs; 2004 May 06; 64 Suppl 2():43-60. PubMed ID: 15765890
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Coronary heart disease benefits from blood pressure and lipid-lowering.
    Sever PS, Poulter NR, Mastorantonakis S, Chang CL, Dahlof B, Wedel H, ASCOT Investigators.
    Int J Cardiol; 2009 Jun 26; 135(2):218-22. PubMed ID: 19232755
    [Abstract] [Full Text] [Related]

  • 20. Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events.
    Plosker GL, Lyseng-Williamson KA.
    Pharmacoeconomics; 2007 Jun 26; 25(12):1031-53. PubMed ID: 18047388
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.